busulfan 16 mg/kg and cyclophosphamide 200 mg/kg (BU/CY). 14 Due to the high incidence of treatment-related mortality with 200 mg/kg of cyclophosphamide, the dose was The combination of busulfan and cyclophosphamide has seldom been employed as a conditioning regimen for lowered to 120 mg/kg (BU/CY). [15] [16] [17] Although busulfancontaining regimens are increasingly being used in autologpatients with lymphoma. Twenty patients with relapsed or refractory lymphoma were treated with busulfan (16 ous transplantation, their role in the treatment of lymphoma remains undefined. Only a few series have been reported mg/kg) and cyclophosphamide (120 mg/kg) (BU/CY) followed by peripheral blood stem cell rescue in 19 patients using BU/CY as the conditioning regimen in patients with a diagnosis of lymphoma undergoing stem cell transplanor autologous bone marrow in one patient. There were 12 females and eight males, with a median age of 48 tation. [18] [19] [20] [21] [22] We report 20 patients with a diagnosis of lymphoma transplanted using BU/CY as the conditioning years (range 30-65). Four patients had Hodgkin's disease, and 16 patients had non-Hodgkin's lymphoma.
(rh G-CSF) (Neupogen; Amgen, Thousand Oaks, CA, Study definitions and statistics USA) at 5 g/kg/day in four patients and following the Overall survival was measured in months and was defined administration of rh G-CSF at 5 g/kg/day and chemoas the time from the day of transplantation until death from therapy in 15 patients. PBSCs were collected at the time any cause. Progression-free survival was defined as the time of hematopoietic recovery starting when leukocyte and from the day of transplantation until disease relapse/ platelet counts reached 1 × 10 9 /l and 50 × 10 9 /l, respectprogression or death from any cause. Relapse was defined ively. PBSCs were obtained daily by 4-h leukapheresis as relapsed disease after achieving a complete remission (COBE Spectra; COBE BCT, Lakewood, CO, USA) until to transplantation. Disease progression was defined as an the total collected mononuclear cell count was 7 × 10 8 /kg. increase in disease bulk after achieving a partial response Total cell counts were determined on an automated cell or an initial nonprogressive commuted demographic (CT) counter (Coulter ZM; Coulter, Hialeah, FL, USA). The abnormality after transplantation. Status at transplant was pheresis product was mixed with 10% DMSO (v/v, defined by two main criteria. The first was response to Cryoserv; Research Industries, Salt Lake City, UT, USA).
initial treatment as assessed by changes in tumor mass. The cell concentration was adjusted not to exceed 2 × 10 8 Changes in tumor mass were assessed as a percentage cells/ml and 60 ml aliquots were transferred to bags (Cell change of the initial mass. Complete remission (CR) was Freeze Cryogenic Storage Containers; Chartermed, Lakedefined as complete disappearance of all evidence of lymwood, NJ, USA) for controlled rate freezing. The bags were phoma. A partial remission (PR) was defined as more than stored in liquid nitrogen and thawed in a 37°C water bath 50% decrease in all measurable disease. The second criteria at the bedside immediately prior to infusion. The total numwas response to any salvage therapy at the time of relapse. ber of CD34 + and lineage negative (CD34 + lin − ) cells were Patients with disease that showed at least PR to convendetermined in daily PBSC products by flow cytometry by tional dose salvage chemotherapy were defined as having staining cells with two anti-CD34, fluorescein isothiocyansensitive relapse and those with no response or less than ate-conjugated monoclonal antibodies, 8GT12 (Becton 50% response to such treatment were defined as having Dickinson, San Jose, CA, USA) and Qbend-10 (Gen Track, resistant relapse. Patients with relapsed disease who proPlymouth, PA, USA) and four lineage-specific phycoerceeded to transplant without any chemotherapy at the time ythrin-conjugated monoclonal antibodies with specificities of relapse were considered to be in an untested relapse. for CD3, CD11B, CD14 and CD19 (Becton Dickinson). 24 Early procedure-related mortality was defined as that within Granulocyte-macrophage colony forming units (CFU-GM) 100 days of transplant therapy, and as toxic mortality if were assayed using a methylcellulose culture system 25 and this was due to recognized complication of the procedure. scored after 14 days of incubation.
Disease response was assessed by CT at 1 month, 3 months, 6 months, and annually thereafter. Kaplan-Meier estimates of survival and associated 95% confidence intervals were obtained using standard methods. 26 Regimen-related toxPreparative regimen icity was graded using a previously described system to A total dose of busulfan of 16 mg/kg was administered assess morbidity. 27 orally in four divided daily doses over 4 days. Cyclophosphamide 60 mg/kg was administered intravenously over 2 Results h daily for 2 days. Phenytoin was routinely given to prevent busulfan-induced seizures starting the day prior to the Patient characteristics initiation of the conditioning regimen until 2 days after administation of busulfan. Uroepithelial prophylaxis was Twenty patients between the ages of 30-65 years with NHL achieved with intravenous hydration and bladder irrigation.
or HD were transplanted using BU/CY as the conditioning Bone marrow or PBSCs were infused 48 h after the second regimen. Patient characteristics are shown in Table 1 . dose of cyclophosphamide.
Twelve patients were female and eight were male. Four patients had the diagnosis of HD and 16 patients had the diagnosis of NHL. Amongst the patients with the diagnosis of NHL, four had low-grade lymphoma, 11 had intermediSupportive care ate-grade lymphoma, and one patient had high-grade lymphoma. Among the patients with HD, three had a diagnosis All patients were cared for in private rooms with positive pressure, high efficiency particle infiltration (HEPA) air of nodular sclerosing HD, and one patient had a diagnosis of lymphocyte-depleted HD. Three patients with HD had system. All patients received antimicrobial prophylaxis with ciprofloxacin. Acyclovir was routinely used in patients stage III at diagnosis, and one patient had stage IV. Ten patients with NHL had stage IV at diagnosis, five patients with elevated herpes simplex antibody titers. All blood products were filtered and irradiated. Parental nutrition and had stage III, and one patient had stage I. This patient relapsed with central nervous system involvement (CNS) broad spectrum antibiotic coverage was provided as needed. Patients were transfused with leukocyte-free and, for that reason, was considered for transplantation after treatment of CNS disease. Serum lactic dehydrogenase packed RBCs and platelets to maintain hemoglobin values greater than 8 g/dl and platelet count greater than (LDH) at diagnosis levels were not available for five patients. The LDH was elevated in seven patients and nor-10 × 10 9 /l. Rh G-CSF at 5 g/kg/day was given subcutaneously from the day after transplantation until engraftment. mal in eight patients. Ten patients were transplanted in first 779 the patient who received bone marrow, the number of days NED 4 (20) to recovery of neutrophil count to greater than 0.5 × 10 9 /l I 0 (0) was 28, and to a platelet count greater than 20 × 10 9 /l was II 3 (15) III 5 (25) 140. This patient had received craniospinal irradiation IV 8 (40) immediately prior to administration of the conditioning Disease histology (%) regimen due to a history of prior CNS involvement. For
Hodgkin's disease 4 (20) patients receiving PBSC, the median number of days to Low-grade lymphoma 4 (20) recovery of neutrophil count to greater than 0. number of days to platelet recovery was 18 (range 9-39).
Bone marrow status at transplant (%)
Of the patients who did not achieve platelet engraftment Positive 3 (15) within 100 days, one had massive splenomegaly and had Negative 15 (75) been previously treated with eight chemotherapy regimens.
Unknown 2 (10) One of these patient also had massive splenomegaly and
Prior CNS involvement (%) 1 (5) had received radiation therapy to the pelvic area. Another
Prior radiation therapy (%) 5 (25) patient had previously harvested marrow stored in another institution, and this marrow was infused 4 months after BM = bone marrow; PBSC = peripheral blood stem cell.
PBSC transplant. This patient had a relatively low dose of CD34 + cells infused (2.42 × 10 6 /kg). The median number of times red blood cells were transfused was six (range relapse; six patients were considered to have primary refractory disease, and four other patients were transplanted 2-23). In the 16 patients who demonstrated full platelet engraftment, the median number of times platelets were with more advanced disease (two in third CR and two in fourth CR). Of the 10 patients transplanted in first relapse, transfused was 18 (range 0-90). four had chemotherapy resistant disease and six patients had chemosensitive disease. Treatment of relapse prior to Morbidity and mortality transplantation was not standardized. Five patients also received radiation therapy, but none had mediastinal Mucositis was common, but severe mucositis (grade IV) did not occur in any of the patients. Only three patients irradiation. Two patients had a previous transplant. One of these patients had a diagnosis of HD and had undergone developed grade III mucositis, two of which required parenteral nutrition. Hemorrhagic cystitis was not seen in this an autologous bone marrow transplant in second CR 2 years previously. As a preparative regimen, she had received ifospatient population. No seizures occurred during busulfan administration. Neutropenic fevers occurred in 19 patients. famide, carboplatin and etoposide. She relapsed 2 years post-transplant and received salvage therapy achieving a Blood cultures were negative in 12 patients and positive in seven. None of the positive cultures were due to gramthird CR. The second patient had a diagnosis of NHL, intermediate grade and had undergone an autologous bone marnegative organisms. No patients developed fungal infections. Three patients developed the syndrome of venorow transplant also with second CR. She received cyclophosphamide and total body irradiation as the conditioning occlusive disease (VOD). Maximum bilirubin in these three patients was 3.8 mg/dl, 7.3 mg/dl and 4.2 mg/dl (normal regimen. She relapsed 4 years after that transplant.
Ͻ2 mg/dl). One patient developed interstitial pneumonitis. Bronchoscopy with bronchoalveolar lavage failed to reveal Peripheral progenitor cell collection a causative organism. No other significant grade III or higher abnormalities of hepatic, renal or cardiac function Apheresis was performed following administration of rh G-CSF alone in four patients, or rh G-CSF and chemotherapy were observed in the remaining patients. Two patients developed herpes zoster, and one patient developed myeloin 15 patients. The chemotherapy mobilization regimen varied from patient to patient. Ten patients received single dysplastic syndrome (MDS). The myelodysplastic syndrome was diagnosed 13 months after transplantation. The agent ifosphamide at 12 g/m 2 , four patients received DHAP (dexamethasone, high-dose cytarabine and cisplatin) and patient developed progressive pancytopenia and a bone marrow was consistent with MDS. Cytogenetics showed an one patient received ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin). Leukapheresis abnormality of chromosome 7. This patient had a diagnosis of HD and had previously received MOPP chemotherapy. was devoid of any significant morbidity. The median number of leukaphereses was six (range 3-11 patients with NHL treated with BU/CY and PBSC transplantation. There was no regimen-related mortality, and the four patients had no evidence of disease at the time of transplant and one was too early to be evaluated. All patients, morbidity was minimal. With a median follow-up of 11 months, the probability of event-free survival was 57%. however, are included in the survival analysis. Following transplantation, eight patients (51%) achieved CR while
Here, we report a series of 20 patients with a diagnosis of refractory or relapsed lymphoma using BU/CY as confive patients (33%) achieved PR and two patients had progressive disease. Of the eight patients in CR following ditioning regimen. Using this regimen, there has been no treatment-related mortality and the morbidity was accept-BU/CY, two patients remain alive with no evidence of disease at 6 and 26 months post-transplantation. Of the able. The neutrophil recovery was rapid in the 19 patients receiving PBSCs (median day to neutrophil recovery was remaining CRs, one patient is alive but has progressed, four patients progressed and died of their disease, and one 12 days). Rapid neutrophil engraftment has been reported by others. Ballester et al 22 reported on 61 patients with varipatient, while in complete remission, died suddenly. Of the patients who achieved a PR post-transplantation, two are ous hematological malignancies. Twenty-one of these patients had the diagnosis of lymphoma. Neutrophil alive with no disease progression at 8 and 35 months posttransplant. Of the four patients transplanted with no eviengraftment occurred at a median of 10 days posttransplant. In our series, three patients failed to achieve a dence of disease, one patient died of disease progression, two patients have progressed but are still alive, and another platelet count of 20 × 10 6 /l by 100 days post-transplant. These three patients were heavily pretreated and had a relapatient continues to be in CR at 27 months post-transplant. The median follow-up duration after high-dose chemotively low number of CD34 + cells in the graft (less than 5 × 10 6 CD34 + /kg). One patient in our series developed therapy is 30 months (range 1-42). Figure 1 shows the Kaplan-Meier estimate of the overall survival, which is myelodysplastic syndrome (MDS). Acute myelogenous leukemia and myelodysplasia have only been described projected to be 50% at 2 years. Event-free survival is estimated to be at 33% at 2 years.
infrequently following transplantation for Hodgkin's disease. 28 The occurrence of MDS in this patient is most likely related to his initial treatment with MOPP chemotherapy. 29 The overall response rate in this group was 84%, with 51% Discussion of patients achieving a CR. The event-free survival at 2 years is 33%. These results, which are skewed towards a There is no evidence for a superior high-dose chemotherapy regimen in the treatment of relapsed/refractory lymphoma.
worse prognostic group of patients with lymphoma, reflect that the use of BU/CY seems to have sufficient antilymWhether or not there are differences in outcome between the various regimens employed is uncertain. Given the hetphoma activity to warrant further investigation. erogeneity of the patient population, it is not surprising that no differences have been observed so far. Toxicity due to the conditioning regimen is a major cause of early mortality Acknowledgements post-transplant. Long-term outcome after transplants for relapsed/refractory lymphoma can be reduced significantly
The authors would like to thank Mary Dennis for the preparation by regimen-related toxicity. The majority of the regimens of this manuscript.
used as a preparative regimen for the treatment of lymphomas use either TBI or contain a nitrosourea. Bearman et al 7 report a 22% incidence of grade III or IV regimenReferences related toxicity and a 12% regimen-related mortality for patients with relapsed lymphoma undergoing transplant 1 Philip T, Armitage JO, Spitzer G et al. High-dose therapy and using a TBI-based regimen. [8] [9] [10] In recent studies, up to 18% nancies who had previously received mantle radiation.
